The goal of this proposal is to support innovative patient oriented translational research through 1) developing tissue based biomarkers to guide the development of anti-angiogenesis drugs, and 2) development and mentoring of junior clinical researchers. The importance of anti-VEGF therapy has been validated in a phase III clinical trial of bevacizumab in patients with metastatic colorectal cancer. However, bevacizumab may have side effects such as increased risks of GI perforation, peri-operative wound healing complications, and arterial vascular events. These toxicities may be related to the role of VEGF in wound healing. Angiogenic responses in tumors and wounds utilize similar cellular, matrix, and growth factor components. Also, wound healing gene expression profiles are conserved between granulation tissue and multiple tumor types. To exploit these similarities and understand the effects of angiogenesis inhibitors on wound healing, we have developed a safe and convenient dermal wound angiogenesis assay. Based upon preclinical resistance mechanisms, the efficacy and toxicity profile of bevacizumab in the clinic, and our preliminary preclinical and clinical data, we will use paired pre- and on- treatment tumor and wound biopsies to test the hypothesis that bevacizumab treatment will have the following molecular and physiological consequences in both tumors and wounds in patients. Anti-VEGF therapy will 1) inhibit VEGFR2 phosphorylation, 2) inhibit neovascularization; 3) upregulate compensatory VEGF ligands and receptors; 4) upregulate compensatory non-VEGF angiogenic factors; and 5) upregulate specific angiogenic gene expression profiles. We hypothesize that these effects will be highly correlated in both tumors and wounds. This project will establish whether wound angiogenesis can serve as a clinical mechanism-based biomarker for anti-VEGF therapies. These studies will determine which effects of anti-VEGF therapy in tumors and wounds are similar and distinct, with a focus on mechanisms of sensitivity, toxicity, and resistance that are targetable. This work has the potential to improve both the safety and efficacy of this novel class of drugs. ? ? In the context of this work, junior investigators will be trained in clinical research related to anti-angiogenesis agents. Trainees will have specific educational and research experiences, including the development and oversight of several biomarker studies. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
1K24CA113755-01A1
Application #
7036879
Study Section
Special Emphasis Panel (ZCA1-SRRB-4 (O2))
Program Officer
Gorelic, Lester S
Project Start
2006-09-01
Project End
2011-06-30
Budget Start
2006-09-01
Budget End
2007-06-30
Support Year
1
Fiscal Year
2006
Total Cost
$118,663
Indirect Cost
Name
Duke University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Jia, Jingquan; Dellinger, Andrew E; Weiss, Eric S et al. (2015) Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing. Clin Cancer Res 21:3442-52
Meadows, Kellen L; Rushing, Christel; Honeycutt, Wanda et al. (2015) Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study. Support Care Cancer 23:1311-9
Rangwala, Fatima; Bendell, Johanna C; Kozloff, Mark F et al. (2014) Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. Invest New Drugs 32:700-9
Strickler, John H; McCall, Shannon; Nixon, Andrew B et al. (2014) Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Invest New Drugs 32:330-9
Clarke, Jeffrey Melson; Hurwitz, Herbert I (2013) Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther 13:1187-96
Jia, Jingquan; Starodub, Alex; Cushman, Ian et al. (2013) Dual inhibition of ?V integrins and Src kinase activity as a combination therapy strategy for colorectal cancer. Anticancer Drugs 24:237-50
Liu, Yingmiao; Starr, Mark D; Bulusu, Anuradha et al. (2013) Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. Cancer Med 2:234-42
Innocenti, Federico; Owzar, Kouros; Cox, Nancy L et al. (2012) A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res 18:577-84
Strickler, John H; Starodub, Alexander N; Jia, Jingquan et al. (2012) Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. Cancer Chemother Pharmacol 70:251-8
Palta, Manisha; Patel, Pretesh; Broadwater, Gloria et al. (2012) Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy. Ann Surg Oncol 19:1535-40

Showing the most recent 10 out of 20 publications